The 4 most recent market catalysts affecting $TECH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 95
Bio-Techne Reports Q1 Fiscal 2027 Results and Advances Merck KGaA Merger
Bio-Techne announced robust Q1 fiscal 2027 results, exceeding analyst estimates for both adjusted EPS and net sales, indicating strong operational performance. The most significant…
Oct 27, 2026
Corporate Catalyst
Bearish
Impact 65
Argus Downgrades Bio-Techne to Sell From Buy
Argus, a financial services firm, has downgraded Bio-Techne Corporation's stock rating from Buy to Sell. This change reflects a more pessimistic outlook from the analyst, which can…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
Bio-Techne Opens New Bristol Facility
Bio-Techne (TECH) announced the opening of a new facility in Bristol, which significantly strengthens its global GMP manufacturing capabilities for cell therapy applications and ex…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 75
Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
Bio-Techne's Q4 earnings report shows a mixed financial performance. While the company successfully beat sales estimates by 2.07% and achieved a 1.33% increase in sales year-over-y…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.